鼻内右美托咪定与吸入一氧化二氮用于儿童程序性镇静镇痛的随机临床试验
这项前瞻性、等量随机、开放标签、非劣效性试验在儿科急诊科开展,纳入既往健康、3–15岁、因四肢骨折或脱位或烧伤需程序性镇静镇痛的儿童,随机接受鼻内右美托咪定或吸入一氧化二氮。主要终点为操作期间最高疼痛水平(FLACC量表),鼻内右美托咪定组中位4(IQR 3–6),一氧化二氮组中位4(IQR 2–6),组间差值中位0(95%CI 0–1),鼻内右美托咪定不劣于一氧化二氮。同一镇静镇痛方式接受度:儿童鼻内右美托咪定组52/74(82.5%)vs 一氧化二氮组59/74(88.1%),家长65/74(91.5%)vs 70/74(94.6%)。未报告严重不良事件。作者结论支持鼻内右美托咪定可考虑作为50%一氧化二氮的替代方案。
要点
- 3–15岁四肢骨折/脱位或烧伤儿童程序性镇静镇痛,鼻内右美托咪定组操作期间最高FLACC中位4(IQR 3–6),一氧化二氮组中位4(IQR 2–6)。
- 组间FLACC差值中位0(95%CI 0–1),鼻内右美托咪定在操作期间疼痛水平上不劣于一氧化二氮。
- 同一镇静镇痛方式儿童接受度:鼻内右美托咪定组52/74(82.5%)vs 一氧化二氮组59/74(88.1%);家长接受度65/74(91.5%)vs 70/74(94.6%)。
- 试验未报告严重不良事件。
- 作者认为鼻内右美托咪定可考虑作为50%一氧化二氮用于3–15岁儿童程序性镇静镇痛的替代方案。
适用人群与场景
- 儿科急诊科中既往健康、3–15岁、因四肢骨折或脱位或烧伤需程序性镇静镇痛的儿童。
处置流程与药物剂量
- 随机接受鼻内右美托咪定或吸入一氧化二氮(原文结论表述为50%一氧化二氮)。
- 操作期间以FLACC量表评估最高疼痛水平。
研究设计与关键结果
- 研究类型:前瞻性、等量随机、开放标签、非劣效性试验,在儿科急诊科开展。
- 人群:既往健康、3–15岁、四肢骨折或脱位或烧伤需程序性镇静镇痛的儿童。
- 干预与对照:鼻内右美托咪定 vs 吸入一氧化二氮。
- 主要终点:操作期间最高FLACC,鼻内右美托咪定组中位4(IQR 3–6),一氧化二氮组中位4(IQR 2–6);组间差值中位0(95%CI 0–1),鼻内右美托咪定不劣于一氧化二氮。
- 同一镇静镇痛方式接受度:儿童鼻内右美托咪定组52/74(82.5%)vs 一氧化二氮组59/74(88.1%);家长鼻内右美托咪定组65/74(91.5%)vs 一氧化二氮组70/74(94.6%)。
- 不良事件:未报告严重不良事件。
证据类型、等级与局限
- 证据类型:前瞻性、等量随机、开放标签、非劣效性临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为鼻内右美托咪定不劣于50%一氧化二氮,可考虑作为50%一氧化二氮用于3–15岁儿童程序性镇静镇痛的替代方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Procedural sedation and analgesia is an important part of pediatric emergency care, safe and clinically useful alternatives for adequate management are necessary. The objective of this clinical trial was to evaluate the non-inferiority of intranasal dexmedetomidine to nitrous oxide with respect to analgesia for a painful procedure in children 3-15 years of age.
METHODS: This prospective, equally randomized, open-label, non-inferiority trial was conducted at a Pediatric Emergency Department. Previously healthy children 3-15 years of age, with an extremity fracture or luxation or a burn and requiring procedural sedation and analgesia were eligible. Patients were randomized to receive either intranasal dexmedetomidine or inhaled nitrous oxide. The primary outcome measure was highest pain level during the procedure, assessed with Face, Legs, Activity, Cry, Consolability scale (FLACC). Mann-Whitney U test (continuous variables) and Fisher's test (categorical variables) were used for statistical analysis.
RESULTS: The highest FLACC was median 4 (IQR 3-6) with intranasal dexmedetomidine and median 4 (IQR 2-6) with nitrous oxide. The median of the difference between samples from each group for FLACC was 0 with 95%CI (0-1), thus intranasal dexmedetomidine was not inferior to nitrous oxide with respect to the level of pain during the procedure. The same method for procedural sedation and analgesia would be accepted by 52/74 (82.5%) children and 65/74 (91.5%) parents in the intranasal dexmedetomidine group respectively 59/74 (88.1%) versus 70/74 (94.6%) with nitrous oxide. No serious adverse events were reported.
CONCLUSIONS: The results of this trial support that intranasal dexmedetomidine is not inferior to 50% nitrous oxide in providing analgesia for a painful procedure in children 3-15 years of age and can be considered as an alternative to 50% nitrous oxide for procedural sedation and analgesia.
TRIAL REGISTRATION: EudraCT 201,600,377,317, April 20, 2017. https://eudract.ema.europa.eu/ .
参考来源
- Nikula A, Rinder MR, Lundeberg S, et al. A randomized clinical trial of intranasal dexmedetomidine versus inhaled nitrous oxide for procedural sedation and analgesia in children. Scand J Trauma Resusc Emerg Med. 2024. PMID: 39568028. doi:10.1186/s13049-024-01292-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。